Table 2. Treatment with adefovir dipivoxil modulates the clinical profiles of IA patients.

Group	Drug responded (n = 15)		Drug non-response (n = 8)
	Before	After	Before	After
ALT (U/L)	125 (46–2343)	42 (23–69)*	130 (112–1138)	68 (39–127)*
AST (U/L)	104.5 (24–787)	39 (23–47)*	89 (48–876)	35 (16–65)*
HBVDNA (log10copies/ml)	6.0 (5.2–7.0)	2.5 (0.3–3.1)*	5.8 (3.7–7.5)	4.9 (2.4–6.7)
HBsAg (IU/ml)	5002.04 (1243.65–55925.04)	3478.45 (890.34–17118.09)	4239.8 (224.59–22160.14)	4965.49 (654.8–18420.66)
HBsAb (mIU/ml)	0.01 (0–3.71)	0.4 (0–4.41)	0 (0–3.2)	0.55(0–3.85)
HBeAg (S/CO)	2189.6 (3.88–4094.10)*	539.62 (0.47–2345.67)*	555.855 (1.311–5573.35)	284.626 (3.24–4167.3)
HBeAb (S/CO)	16.71(0.02–46.74)*	1.26(0.01–35.67)*	32.55 (0.83–44.76)	13.23 (1.16–32.59)

Data are expressed as median (range) or real case numbers.

*P<0.05 vs. before treatment.